TKTakatoshi Koroki

Takatoshi Koroki

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Takatoshi Koroki has a total of 18 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Contamination of Blood Cultures Drawn From Arterial Catheters Versus Venipuncture or Venous Catheters in Critically Ill Patients: A Systematic Review and Meta-analysis

    by Takatoshi Koroki, Motoki Fujii, Yuki Kotani, Takahiko Yaguchi, Taisuke Shibata, Chihiro Hirata, Naoki Okawa, Koshi Ota, Mayuko Tonai, Toshiyuki Karumai, et al.

    Background: Arterial catheter–drawn blood culture sampling may reduce patient discomfort and healthcare providers' workload. Guidelines discourage transcatheter blood culture collection due to contamination risks, mainly derived from data on venous catheter–drawn cultures. However, contamination rates of arterial catheter–drawn cultures have not been comprehensively evaluated compared with venipuncture- or venous catheter–drawn cultures. Methods: We searched PubMed, Embase, and the Cochrane Library from inception through 5 December 2023, for studies comparing arterial catheter–drawn blood cultures with venipuncture- or venous catheter–drawn blood cultures. The primary outcome was blood culture contamination rate. We performed a random-effects meta-analysis and evaluated the certainty of the evidence using the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) methodology. Results: We included 6 studies involving 8533 blood cultures. When comparing arterial catheter– with venipuncture-drawn cultures, the crude contamination rates were 28/1355 (2.1%) and 103/4539 (2.3%), respectively. Arterial catheter–drawn cultures may not increase contamination rates compared to venipuncture-drawn cultures (risk difference [RD], 0.01 [95% confidence interval {CI}, −.01 to .02]; low certainty). When comparing arterial catheter– with venous catheter–drawn cultures, the crude contamination rates were 15/489 (3.1%) and 211/2639 (8.0%), respectively. Compared to venous catheter–drawn cultures, arterial catheter–drawn cultures may have lower contamination rates (RD, −0.05 [95% CI, −.11 to .01]; low certainty). Conclusions: In critically ill patients, arterial catheter–drawn blood cultures may have contamination rates comparable to venipuncture-drawn cultures and potentially lower than venous catheter–drawn cultures. Clinical Trials Registration: PROSPERO (CRD42023486227).


  • Open Access

    Severe Traumatic Brain Injury in a Patient with von Willebrand Disease Type 2A Successfully Treated with Factor VIII/von Willebrand Factor Concentrates: A Case Report

    by Takatoshi Koroki, Tomohiro Abe, Sachiyo Kamimura, Hidenobu Ochiai

    Rare disease von Willebrand disease (VWD) is characterized by a bleeding tendency due to abnormalities in von Willebrand factor (VWF). Severe traumatic brain injury (TBI) can induce secondary coagulopathy and hemostatic disorders. We herein present a rare case of multiple trauma, including severe TBI, in a patient with VWD who was successfully treated with repeated factor VIII/VWF transfusion in addition to standard critical care. A 22-year-old man with type 2A VWD sustained head and lower limb injuries in a traffic accident and was comatose. Computed tomography indicated multiple trauma, including severe TBI (left-sided traumatic epidural hematoma, left-sided traumatic subdural hematoma, traumatic subarachnoid hemorrhage, skull fracture, and skull base fracture). The patient underwent emergency craniotomy for hematoma removal, external decompression, and intracranial pressure monitoring along with massive transfusion and repeated perioperative transfusion of factor VIII/VWF concentrates according to the level of bleeding. He recovered consciousness and eventually survived without neurological deficits. Multiple trauma including TBI in patients with VWD is a critical condition. The active transfusion of factor VIII/VWF is essential for controlling hemorrhage early and in the perioperative period.


  • Open Access

    Successful covered stent‐graft treatment of superficial femoral arterial injury due to blunt trauma

    by Takatoshi Koroki, Takuya Kuroki, Tomohiro Abe, Eiji Furukoji, Hidenobu Ochiai

    Background: Endovascular treatment is used for traumatic arterial injuries in the torso. However, the effectiveness of endovascular covered stent‐graft treatment for peripheral artery injury is unclear. We present a case of superficial femoral artery (SFA) injury successfully treated with a covered stent‐graft.Case Report: A 68‐year‐old man presented with traumatic lower limb injury and shock. Computed tomography angiography revealed left subtrochanteric fracture and hematoma with extravasation. Digital subtraction angiography revealed extravasation from a left SFA branch, and a pseudoaneurysm at the SFA trunk. We coil embolized the SFA branch, and treated the pseudoaneurysm with a covered stent‐graft. Computed tomography carried out 22 days later showed complete pseudoaneurysm exclusion and sufficient stent patency.Conclusion: We successfully used a covered stent‐graft to treat SFA injury due to blunt trauma. A covered stent‐graft could be effective for peripheral artery injury.


  • Open Access

    Nicardipine Versus Nitroglycerin for The Treatment of Hypertensive Acute Heart Failure Syndrome: A Single-Center Observational Study

    by Takatoshi Koroki, Tomohiro Abe, Hidenobu Ochiai

    Background: Nitroglycerin is considered a first-line agent for hypertensive acute heart failure syndromes (AHFS). In this study, we compared the effectiveness of nicardipine and nitroglycerin in patients with hypertensive AHFS. Methods: We conducted a single-center, retrospective, observational study at the intensive care unit of a Japanese hospital. Patients diagnosed with AHFS and systolic blood pressure exceeding 140 mmHg on arrival between April 2013 and August 2019 were included. The outcomes were the time to optimal blood pressure control, duration of the continuous infusion of anti-hypertensive agents, duration of positive pressure ventilation, need for additional anti-hypertensive agents, length of hospital stay, and body weight changes. Outcomes were compared between the nicardipine and nitroglycerin groups. We also compared these outcomes between the groups after excluding patients who received renal replacement therapy. Results: Forty-five patients were enrolled (25 and 20 were treated with nitroglycerin and nicardipine, respectively). The nicardipine group had a shorter time to optimal blood pressure control (1.0 [interquartile range, 1.0–3.0] h vs. 0.5 [0.5–1.0] h), shorter duration of the continuous infusion of anti-hypertensive agents (65.5 [32.5–127.5] h vs. 31.0 [18.5–61.0] h), less frequent need for additional anti-hypertensive agents (0 patients vs. 10 patients [40.0%]), and shorter length of hospital stay (19.0 [10.0–33.0] days vs. 8.0 [5.0–12.3] days) than the nitroglycerin group. The duration of positive pressure ventilation and body weight changes were similar between the groups. These outcomes were similar after excluding patients who received renal replacement therapy. Conclusions: Nicardipine may be more effective than nitroglycerin for treating hypertensive AHFS.